Hong Mu

3.4k citations

67 papers · 1.7k indexed · h-index 24

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 25
- Acute Myeloid Leukemia Research 15
- Chronic Myeloid Leukemia Treatments 10
Immunology 21
- Immunotherapy and Immune Responses 7

Co-authors: Michael Andreeff Vivian Ruvolo Marina Konopleva Changyi Chen Po Yee Mak Duncan H. Mak Joel Johansson Bing Z. Carter
Journals: Blood (24 papers)Molecular Cancer Therapeutics (4 papers)Cancer Research (4 papers)Journal of Surgical Research (3 papers)Leukemia (3 papers)
Partner nations: United States China Japan

In The Last Decade

Hong Mu

65 papers receiving 1.7k citations

Peers

Countries citing papers authored by Hong Mu

Since Specialization

Citations

This map shows the geographic impact of Hong Mu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Mu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Mu more than expected).

Fields of papers citing papers by Hong Mu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong Mu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Mu. The network helps show where Hong Mu may publish in the future.

Co-authors

The 25 scholars most cited alongside Hong Mu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hong Mu Line = papers co-authored together Hong Mu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL Leukemia ·Sujan Piya, Ya‐Ling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Mu, Hua He, Vivian Ruvolo, Natalia Baran, R. Eric Davis, Abhinav K. Jain, Marina Konopleava, Hagop M. Kantarjian, Michael Andreeff, M. James You, Gautam Borthakur	2022	23
2	Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia Molecular Cancer Therapeutics ·Xiangmeng Wang, Po Yee Mak, Hong Mu, Wenjing Tao, Arvind Rao, Visweswaran Ravikumar, Vivian Ruvolo, Jonathan A. Pachter, David T. Weaver, Michael Andreeff, Bing Xu, Bing Z. Carter	2020	13
3	An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia–Microenvironment Interactions and Confers Drug Resistance in AML Cancer Research ·Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Wenjing Tao, Vivian Ruvolo, Duncan H. Mak, Hong Mu, Jared K. Burks, Michael Andreeff	2019	49
4	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment Journal of Clinical Investigation ·Sujan Piya, Hong Mu, Seemana Bhattacharya, Philip L. Lorenzi, R. Eric Davis, Teresa McQueen, Vivian Ruvolo, Natalia Baran, Zhiqiang Wang, Yimin Qian, Craig M. Crews, Marina Konopleva, Jo Ishizawa, M. James You, Hagop M. Kantarjian, Michael Andreeff, Gautam Borthakur	2019	56
5	Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model Haematologica ·Bing Z. Carter, Po Yee Mak, Hong Mu, Xiangmeng Wang, Wenjing Tao, Duncan H. Mak, Elisha J. Dettman, Michael H. Cardone, Oleg Zernovak, Takahiko Seki, Michael Andreeff	2019	22
6	Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3 -Mutant Acute Myeloid Leukemia Clinical Cancer Research ·Xuejie Jiang, Po Yee Mak, Hong Mu, Wenjing Tao, Duncan H. Mak, Steven M. Kornblau, Qi Zhang, Peter P. Ruvolo, Jared K. Burks, Weiguo Zhang, Teresa McQueen, Rongqing Pan, Hongsheng Zhou, Marina Konopleva, Jörge E. Cortes, Qifa Liu, Michael Andreeff, Bing Z. Carter	2018	67
7	ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK–AKT–mTOR Signaling Pathway Molecular Cancer Therapeutics ·Khoa Nguyen, Yuanqing Yan, Bin Yuan, Abhishek Dasgupta, Jeffrey Sun, Hong Mu, Kim‐Anh Do, Naoto T. Ueno, Michael Andreeff, V. Lokesh Battula	2018	71
8	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial Haematologica ·Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff	2018	34
9	Focal Adhesion Kinase as a Potential Target in AML and MDS Molecular Cancer Therapeutics ·Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Hui Yang, Guillermo Garcia‐Manero, Duncan H. Mak, Hong Mu, Vivian Ruvolo, Yihua Qiu, Kevin R. Coombes, Nianxiang Zhang, Brittany Knick Ragon, David T. Weaver, Jonathan A. Pachter, Steven M. Kornblau, Michael Andreeff	2017	31
10	Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy Cancer Cell ·Rongqing Pan, Vivian Ruvolo, Hong Mu, Joel Johansson, Gwen Nichols, John C. Reed, Marina Konopleva, Michael Andreeff	2017	204
11	Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo Leukemia ·Hongsheng Zhou, Po Yee Mak, Hong Mu, Duncan H. Mak, Zhihong Zeng, Jörge E. Cortes, Qianshi Liu, Michael Andreeff, B Z Carter	2017	73
12	The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations Cancer Research ·Weiguo Zhang, Gautam Borthakur, Gao Chen, Ye Chen, Hong Mu, Vivian Ruvolo, K. Nomoto, Nanding Zhao, Marina Konopleva, Michael Andreeff	2016	52
13	Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Blood ·Qí Zhāng, Lina Han, Ce Shi, Rongqing Pan, Man Chun John, Jeremy Ryan, Stephen E. Kurtz, Hong Mu, Vivian Ruvolo, Helen Ma, Michael Andreeff, Yingchang Mi, Jeffrey Tyner, Joel Johansson, Anthony Letai, R. Eric Davis, Marina Konopleva	2016	5
14	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia Blood ·Sujan Piya, Steven M. Kornblau, Vivian Ruvolo, Hong Mu, Peter P. Ruvolo, Teresa McQueen, R. Eric Davis, Numsen Hail, Hagop M. Kantarjian, Michael Andreeff, Gautam Borthakur	2016	105
15	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy Blood ·Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Teresa McQueen, Marina Protopopova, Jörge E. Cortes, Joseph R. Marszalek, Sheng‐Bin Peng, Wencai Ma, R. Eric Davis, Donald Thornton, Michael Andreeff, Marina Konopleva	2015	95
16	Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents JNCI Journal of the National Cancer Institute ·Bing Z. Carter, Po Yee Mak, Duncan H. Mak, Yuexi Shi, Yihua Qiu, James M. Bogenberger, Hong Mu, Raoul Tibes, Hui Yao, Kevin R. Coombes, Rodrigo Jácamo, Teresa McQueen, Steven M. Kornblau, Michael Andreeff	2014	61
17	Lysophosphatidic Acid Induces Lymphangiogenesis and IL-8 Production in Vitro in Human Lymphatic Endothelial Cells American Journal Of Pathology ·Hong Mu, Tiffany L. Calderone, Michael A. Davies, Víctor G. Prieto, Hua Wang, Gordon B. Mills, Menashe Bar‐Eli, Jeffrey E. Gershenwald	2012	33
18	Nitrotyrosine promotes human aortic smooth muscle cell migration through oxidative stress and ERK1/2 activation Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Hong Mu, Xinwen Wang, Peter H. Lin, Qizhi Yao, Changyi Chen	2008	17
19	Cyclic strain induces vascular smooth muscle cell differentiation from murine embryonic mesenchymal progenitor cells Surgery ·Gordon M. Riha, Xinwen Wang, Hao Wang, Hong Chai, Hong Mu, Peter H. Lin, Alan B. Lumsden, Qizhi Yao, Changyi Chen	2006	31
20	Cellular and Molecular Mechanisms of Atherosclerosis with Mouse Models Trends in Cardiovascular Medicine ·Ryuji Ohashi, Hong Mu, Qing Yao, Changyi Chen	2004	35

About Hong Mu

Hong Mu is a scholar working on Hematology, Immunology, Oncology, Molecular Biology and Genetics, having authored 67 papers that have together received 1.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (15 papers), Protein Degradation and Inhibitors (11 papers), Cell death mechanisms and regulation (10 papers), Chronic Myeloid Leukemia Treatments (10 papers), Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (7 papers), Histone Deacetylase Inhibitors Research (6 papers) and RNA Interference and Gene Delivery (6 papers). The work is most often cited by research in Hematology (642 citations), Genetics (237 citations), Immunology (346 citations), Molecular Biology (980 citations) and Oncology (362 citations). Hong Mu has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Michael Andreeff, Vivian Ruvolo, Marina Konopleva, Changyi Chen, Po Yee Mak, Duncan H. Mak, Joel Johansson, Bing Z. Carter, Rongqing Pan and Jörge E. Cortes. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Cancer Research, Journal of Surgical Research and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact